---
# System prepended metadata

title: Drug Discovery Services Market Size is Expected to Worth of US$ 33.2  Bn in 2030

---

# Drug Discovery Services Market Size is Expected to Worth of US$ 33.2  Bn in 2030

**The global [drug discovery services market ](https://www.precedenceresearch.com/drug-discovery-services-market)size was estimated at USD 14.11  billion in 2022 and is exprcted to hit around USD 33.2  billion by 2030 with a CAGR of 11.3% from 2022 to 2030.**


**Request a Sample Copy of This Report@ https://www.precedenceresearch.com/sample/1532**

The report has been prepared with extensive primary and secondary research. Primary research involved the majority of the research efforts, wherein analysts carried out interviews with key manufacturers, end-consumers, industry experts, independent consultants, and opinion-makers. 

Secondary research involved referring to company websites, annual reports, investors’ presentations, press releases, patents database, import-export statistics, and other relevant documents to understand the drug discovery services market. Secondary research also included Precedence Research internal repository, industry associations, government agencies, and proprietary databases. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug discovery services market.

The report includes an executive summary, along with a market overview and an elaborative analysis of the growth behavior in various segments that are included in the scope of the study. The report also covers a high-level picture of the production processes and product specifications pertaining to drug discovery services. Furthermore, the report provides insights on the changing competitive dynamics, which serve as valuable tools for existing market players as well as for entities interested in participating in the market.

In addition to the above, the report also explores the competitive landscape, in terms of identifying the global players operating in the drug discovery services market and comprehensive profiles of the key players, including their business overview, key financials, market shares, market footprints, production capacities, and strategic initiatives including new product developments, mergers & acquisitions, etc.


**Some of the prominent players in the global drug discovery services market include:**
Abbott Laboratories Inc.
Advinus Therapeutics
Agilent Technologies Ubiquigent
Albany Molecular Research Inc.
AstraZeneca PLC
Aurigene
Bayer AG
Charles River Laboratories International
ChemBridge Corporation
Covance
**Segments Covered in the Report**
By Process

Target Selection
Target Validation
Hit to Lead Identification
Lead Optimization
Candidate Validation
By Drug Type

Small Molecules
Biologics
By Type

DMPK
Biology Services
Medicinal Chemistry
By Therapeutic Area

Oncology
Cardiovascular Diseases
Diabetes
Neurology
Respiratory Diseases
Others
By Geography

North America
Middle East & Africa (MEA)

**Research Methodology**
Precedence Research employs a comprehensive and iterative research methodology focused on minimizing deviance to provide the most accurate estimates and forecasts possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation which looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:

**Preliminary data mining**
Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.

Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, and pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.

**Statistical model**
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.

Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:
    • Market drivers and restraints, along with their current and expected impact
    • Raw material scenario and supply v/s price trends
    • Regulatory scenario and expected developments
    • Current capacity and expected capacity additions up to 2030
Report content
Qualitative Analysis
•	Industry overview
•	Industry trends
•	Market drivers and restraints
•	Market size
•	Growth prospects
•	Porter’s analysis
•	PESTEL analysis
•	Key market opportunities prioritized
•	Competitive landscape
o	Company overview
o	Financial performance
o	Product benchmarking
o	Latest strategic developments

**Quantitative Analysis**
•	Market size, estimates, and forecast from 2017 to 2030
•	Market estimates and forecast for product segments up to 2030
•	Regional market size and forecast for product segments up to 2030
•	Market estimates and forecast for application segments up to 2030
•	Regional market size and forecast for application segments up to 2030
•	Company financial performance

**TABLE OF CONTENT**
Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Discovery Services Market 

5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Discovery Services Market, By Process

8.1. Drug Discovery Services Market, by Process Type, 2021-2030

8.1.1. Target Selection

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Target Validation

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Hit to Lead Identification

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Lead Optimization

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Candidate Validation

8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug Discovery Services Market, By Drug Type

9.1. Drug Discovery Services Market, by Drug Type, 2021-2030

9.1.1. Small Molecules

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Biologics

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug Discovery Services Market, By Type

10.1. Drug Discovery Services Market, by Type, 2021-2030

10.1.1. DMPK

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Biology Services

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Medicinal Chemistry

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug Discovery Services Market, By Therapeutic Area

11.1. Drug Discovery Services Market, by Therapeutic Area Type, 2021-2030

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2019-2030)

11.1.2. Cardiovascular Diseases

11.1.2.1. Market Revenue and Forecast (2019-2030)

11.1.3. Diabetes

11.1.3.1. Market Revenue and Forecast (2019-2030)

11.1.4. Neurology

11.1.4.1. Market Revenue and Forecast (2019-2030)

11.1.5. Respiratory Diseases

11.1.5.1. Market Revenue and Forecast (2019-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 12. Global Drug Discovery Services Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

Chapter 13. Company Profiles

13.1. Abbott Laboratories Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Advinus Therapeutics

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Agilent Technologies Ubiquigent

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Albany Molecular Research Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Aurigene

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Charles River Laboratories International

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. ChemBridge Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Covance

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms
Immediate Delivery Available |     Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/
 You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Blog: https://www.pharma-geek.com

